In-vitro Colorectal Cancer Screening Tests Market Size 2034

In-vitro Colorectal Cancer Screening Tests Market Growth, Size, Trends Analysis- By Test, By End Use - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Q: How can I get a sample report on the In-vitro Colorectal Cancer Screening Tests Market?

You can get the sample pages by clicking the link - Click Here

Published: Sep-2025	Report ID: HLCA25288	Pages: 1 - 245	Formats^*:
Category : Healthcare

In-vitro Colorectal Cancer Screening Tests Market Introduction and Overview

According to SPER Market Research, the Global In-vitro Colorectal Cancer Screening Tests Market is estimated to reach USD 1.94 billion by 2034 with a CAGR 4.94%.

The report includes an in-depth analysis of the Global In-vitro Colorectal Cancer Screening Tests Market, including market size and trends, product mix, Applications, and supplier analysis. The global In-vitro Colorectal Cancer Screening Tests Market was valued at USD 1.2 billion in 2024 and is expected to grow at a CAGR of over 4.94% from 2025 to 2034. The market is being driven by factors such as the rising incidence of breast and colorectal cancer (CRC), technological advancements, growing demand for personalized medicine, supportive government initiatives, and increased healthcare spending. Notably, the growing prevalence of colon cancer, especially among younger individuals, is expected to significantly boost market growth. This trend highlights the urgent need for effective screening and treatment solutions. Early and accurate detection of colon cancer through in-vitro diagnostic tests plays a critical role in reducing disease burden and improving survival rates, further fueling demand in the market.

By Test:

The fecal occult blood tests (FOBTs) segment leads the in-vitro colorectal cancer screening market, driven by its effectiveness in detecting hidden blood in stoolâ€”a common early sign of colorectal cancer. Widely used in routine screenings, especially for high-risk individuals, FOBTs are recommended as a first-line test in clinical guidelines, reinforcing their dominance. The testâ€™s ability to identify various gastrointestinal conditions, including cancer and polyps, supports its continued use. Advancements by key players and increased regulatory approvals, along with rising cancer prevalence, are further propelling segment growth and market expansion.

By End Use:

Diagnostic laboratories led the market due to their advanced technology, high accuracy, and ability to conduct large volumes of tests like fecal occult blood and biomarker assays. Their expertise and extensive networks make them the preferred choice for colorectal cancer screening. Meanwhile, hospitals and clinics are expected to grow rapidly, driven by rising demand for early diagnosis and noninvasive testing. These facilities are adopting in-vitro tests for their reliability, cost-effectiveness, and ability to detect colorectal cancer in its early stages.

Regional Insights:

North America led the global in-vitro colorectal cancer screening tests market, driven by the rising demand for home-based testing and personalized medicine. The convenience of at-home kits, such as fecal occult blood and DNA-based tests, has made screening more accessible. Additionally, personalized testing based on genetic profiles enhances detection accuracy. In Asia Pacific, the market is growing rapidly due to increasing CRC cases linked to aging and lifestyle changes. Japan dominated the regional market, with strong adoption of biomarker and DNA-based tests that offer early, accurate detection and improved patient outcomes.

Get more information on this report: Download Free Sample PDF

Market Competitive Landscape:

The In-vitro Colorectal Cancer Screening Tests Market is highly consolidated. Some of the market key players are Abbott, Beckman Coulter, Inc., Eiken Chemical Co., Ltd., Epigenomics AG, Immunostics Inc., Kyowa Kirin Co., Ltd., Merck KGaA, Oncocyte Corporation, Quest Diagnostics Incorporated, R-Biopharm AG, Randox Laboratories Ltd., Siemens Healthineers AG.

Recent Developments:

In January 2025, Tempus AI, Inc. introduced its FDA-approved xT CDx, an NGS-based in vitro diagnostic device, in the U.S. Clinicians across the country can now access and utilize this advanced tool to support patient care.

In July 2024, the FDA approved Guardant's innovative blood test, Shield, for colorectal cancer screening. This milestone marks a significant advancement in providing a noninvasive and efficient approach to the early detection of colorectal cancer.

Scope of the report:

Report Metric	Details
Market size available for years	2021-2034
Base year considered	2024
Forecast period	2025-2034
Segments covered	By Test, By End Use
Regions covered	North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa
Companies Covered	Abbott, Beckman Coulter, Inc., Eiken Chemical Co., Ltd., Epigenomics AG, Immunostics Inc., Kyowa Kirin Co., Ltd., Merck KGaA, Oncocyte Corporation, Quest Diagnostics Incorporated, R-Biopharm AG, Randox Laboratories Ltd., Siemens Healthineers AG.

Key Topics Covered in the Report:

Global In-vitro Colorectal Cancer Screening Tests Market Size (FY 2021-FY 2034)
Overview of Global In-vitro Colorectal Cancer Screening Tests Market
Segmentation of Global In-vitro Colorectal Cancer Screening Tests Market By Test (Fecal Occult Blood Tests, Biomarker Tests, Other Methods)
Segmentation of Global In-vitro Colorectal Cancer Screening Tests Market By End-use (Hospitals and Clinics, Diagnostic Laboratories, Others)
Statistical Snap of Global In-vitro Colorectal Cancer Screening Tests Market
Expansion Analysis of Global In-vitro Colorectal Cancer Screening Tests Market
Problems and Obstacles in Global In-vitro Colorectal Cancer Screening Tests Market
Competitive Landscape in the Global In-vitro Colorectal Cancer Screening Tests Market
Details on Current Investment in Global In-vitro Colorectal Cancer Screening Tests Market
Competitive Analysis of Global In-vitro Colorectal Cancer Screening Tests Market
Prominent Players in the Global In-vitro Colorectal Cancer Screening Tests Market
SWOT Analysis of Global In-vitro Colorectal Cancer Screening Tests Market
Global In-vitro Colorectal Cancer Screening Tests Market Future Outlook and Projections (FY 2025-FY 2034)
Recommendations from Analyst

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source

2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPERs internal database
2.1.4. Premium insight from KOLs

2.2. Market size estimation

2.2.1. Top-down and Bottom-up approach

2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis

4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges

5. Market variable and outlook

5.1. SWOT Analysis

5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats

5.2. PESTEL Analysis

5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape

5.3. PORTERs Five Forces

5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry

5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Global In-vitro Colorectal Cancer Screening Tests Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global In-vitro Colorectal Cancer Screening Tests Market

7. Global In-vitro Colorectal Cancer Screening Tests Market, By Test, (USD Million) 2021-2034

7.1. Fecal Occult Blood Tests

7.1.1. Guaiac FOB Stool Test
7.1.2. Immuno-FOB Agglutination Test
7.1.3. Lateral Flow Immuno-FOB Test
7.1.4. Immuno-FOB ELISA Test

7.2. Biomarker Tests
7.3. Other Methods

8. Global In-vitro Colorectal Cancer Screening Tests Market, By End-use, (USD Million) 2021-2034

8.1. Hospitals and Clinics
8.2. Diagnostic Laboratories
8.3. Others

9. Global In-vitro Colorectal Cancer Screening Tests Market, (USD Million) 2021-2034

9.1. Global In-vitro Colorectal Cancer Screening Tests Market Size and Market Share

10. Global In-vitro Colorectal Cancer Screening Tests Market, By Region, 2021-2034 (USD Million)

10.1. Asia-Pacific

10.1.1. Australia
10.1.2. China
10.1.3. India
10.1.4. Japan
10.1.5. South Korea
10.1.6. Rest of Asia-Pacific

10.2. Europe

10.2.1. France
10.2.2. Germany
10.2.3. Italy
10.2.4. Spain
10.2.5. United Kingdom
10.2.6. Rest of Europe

10.3. Middle East and Africa

10.3.1. Kingdom of Saudi Arabia
10.3.2. United Arab Emirates
10.3.3. Qatar
10.3.4. South Africa
10.3.5. Egypt
10.3.6. Morocco
10.3.7. Nigeria
10.3.8. Rest of Middle-East and Africa

10.4. North America

10.4.1. Canada
10.4.2. Mexico
10.4.3. United States

10.5. Latin America

10.5.1. Argentina
10.5.2. Brazil
10.5.3. Rest of Latin America

11. Company Profile

11.1. Abbott

11.1.1. Company details
11.1.2. Financial outlook
11.1.3. Product summary
11.1.4. Recent developments

11.2. Beckman Coulter, Inc.

11.2.1. Company details
11.2.2. Financial outlook
11.2.3. Product summary
11.2.4. Recent developments

11.3. Eiken Chemical Co., Ltd.

11.3.1. Company details
11.3.2. Financial outlook
11.3.3. Product summary
11.3.4. Recent developments

11.4. Epigenomics AG

11.4.1. Company details
11.4.2. Financial outlook
11.4.3. Product summary
11.4.4. Recent developments

11.5. Immunostics Inc.

11.5.1. Company details
11.5.2. Financial outlook
11.5.3. Product summary
11.5.4. Recent developments

11.6. Kyowa Kirin Co., Ltd

11.6.1. Company details
11.6.2. Financial outlook
11.6.3. Product summary
11.6.4. Recent developments

11.7. Merck KGaA

11.7.1. Company details
11.7.2. Financial outlook
11.7.3. Product summary
11.7.4. Recent developments

11.8. Oncocyte Corporation

11.8.1. Company details
11.8.2. Financial outlook
11.8.3. Product summary
11.8.4. Recent developments

11.9. Quest Diagnostics Incorporated

11.9.1. Company details
11.9.2. Financial outlook
11.9.3. Product summary
11.9.4. Recent developments

11.10. R-Biopharm AG

11.10.1. Company details
11.10.2. Financial outlook
11.10.3. Product summary
11.10.4. Recent developments

11.11. Randox Laboratories Ltd.

11.11.1. Company details
11.11.2. Financial outlook
11.11.3. Product summary
11.11.4. Recent developments

11.12. Siemens Healthineers AG

11.12.1. Company details
11.12.2. Financial outlook
11.12.3. Product summary
11.12.4. Recent developments

11.13. Others

12. Conclusion

13. List of Abbreviations

14. Reference Links

SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.

The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.

SPER-Methodology-1

SPER-Methodology-2

SPER-Methodology-3

Frequently Asked Questions About This Report

Who are the key players in In-vitro Colorectal Cancer Screening Tests Market?

Abbott, Beckman Coulter, Inc., Eiken Chemical Co., Ltd., Epigenomics AG, Immunostics Inc., Kyowa Kirin Co., Ltd., Merck KGaA, Oncocyte Corporation, Quest Diagnostics Incorporated, R-Biopharm AG, Randox Laboratories Ltd., Siemens Healthineers AG.

What is the conclusion of the In-vitro Colorectal Cancer Screening Tests Market?

The report includes an in-depth analysis of the Global In-vitro Colorectal Cancer Screening Tests Market, including market size and trends, product mix, Applications, and supplier analysis.

How big is the In-vitro Colorectal Cancer Screening Tests Market?

In-vitro Colorectal Cancer Screening Tests Market is projected to reach USD 1.94 billion by 2034, growing at a CAGR of of 4.94% during the forecast period.

What is the growth rate of the In-vitro Colorectal Cancer Screening Tests Market?

In-vitro Colorectal Cancer Screening Tests Market grew in Market size from 2025. The Market is expected to reach USD 1.94 billion by 2034, at a CAGR of 4.94% during the forecast period.

What is the anticipated CAGR of the In-vitro Colorectal Cancer Screening Tests Market?

In-vitro Colorectal Cancer Screening Tests Market CAGR of 4.94% during the forecast period.

How can I get a sample report on the In-vitro Colorectal Cancer Screening Tests Market?

You can get the sample pages by clicking the link - Click Here

What is the Market size of the In-vitro Colorectal Cancer Screening Tests Market?

In-vitro Colorectal Cancer Screening Tests Market size is USD 1.94 billion from 2025 to 2034.

Which segment is expected to In-vitro Colorectal Cancer Screening Tests Market?

In-vitro Colorectal Cancer Screening Tests Market is covered By Test, By End Use

Which region is expected to have the highest Market share in the In-vitro Colorectal Cancer Screening Tests Market?

The North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa is the highest Market share in the In-vitro Colorectal Cancer Screening Tests Market.